Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Anna Elgart"'
Autor:
Itay, Perlstein, Avia, Merenlender Wagner, Roberto, Gomeni, Michael, Lamson, Eran, Harary, Ofer, Spiegelstein, Attila, Kalmanczhelyi, Ryan, Tiver, Pippa, Loupe, Micha, Levi, Anna, Elgart
Publikováno v:
Clinical Pharmacology in Drug Development. 11:865-877
TV-46000 is a long-acting subcutaneous antipsychotic that uses a novel copolymer drug delivery technology in combination with a well-characterized molecule, risperidone, that is in clinical development as a treatment for schizophrenia. A population p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25cc3216f9f60cc6cdd980c2454bc0e8
https://doi.org/10.1002/cpdd.1078
https://doi.org/10.1002/cpdd.1078
Autor:
Pippa S. Loupe, David J. Greenblatt, Arik A. Zur, Anna Elgart, Dorit Mimrod, Sivan Weiss, Ofer Spiegelstein
Publikováno v:
Clinical Pharmacology in Drug Development. 9:1015-1024
Laquinimod, a neuroimmunomodulator, is extensively metabolized by cytochrome P450 (CYP) 3A4, and modulations of CYP3A4 activity may lead to alterations in the pharmacokinetics and/or clinical effects of laquinimod. To determine the drug-drug interact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac479ac6f68e5f541ad3be627cec9843
https://doi.org/10.1002/cpdd.785
https://doi.org/10.1002/cpdd.785
Publikováno v:
European Journal of Clinical Pharmacology. 75:41-49
Laquinimod is an orally dosed immuno-modulator currently under development for Huntington’s disease (HD). Preclinical findings suggest potential teratogenicity of laquinimod, thus the reproductive ability of females with HD treated with laquinimod
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89cd75fd7be59bf4b20789c991a361d3
https://doi.org/10.1007/s00228-018-2549-7
https://doi.org/10.1007/s00228-018-2549-7
Autor:
Colm Farrell, Ofer Spiegelstein, Alena Y. Edwards, Anna Elgart, Laura Rabinovich-Guilatt, Ofra Barnett-Griness
Publikováno v:
British Journal of Clinical Pharmacology. 83:1932-1943
Aims Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta-analysis evaluated the population pharmacokinetics (PK)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d3c66ad15e0aad71cfff48d14c71f90d
https://doi.org/10.1111/bcp.13287
https://doi.org/10.1111/bcp.13287
Publikováno v:
Basicclinical pharmacologytoxicology. 124(3)
As of March 2018, rasagiline is approved for the treatment of Parkinson disease in 55 countries including Japan. The present study evaluated the pharmacokinetics (PK) and safety of rasagiline in healthy Japanese and Caucasian subjects following singl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9d5a9beb4fb5f6b05be4f8d8677b04ec
https://pubmed.ncbi.nlm.nih.gov/30218626
https://pubmed.ncbi.nlm.nih.gov/30218626
Autor:
Laura Rabinovich-Guilatt, Sandra K. Willsie, Ofer Spiegelstein, Lavi Erisson, Ofra Barnett-Griness, Anna Elgart, Amitkumar Pande, Shoshi Tessler
Publikováno v:
British Journal of Clinical Pharmacology. 80:436-445
Aims Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide (ASO) that reduces clusterin production, is under investigation with chemotherapy in patients with solid tumours. Custirsen is associated with constitutional symptoms (CS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cfddf23a0b09d60ae1c91e78f0f1a8a2
https://doi.org/10.1111/bcp.12633
https://doi.org/10.1111/bcp.12633
Autor:
Anna Elgart, Eli Eyal, Joel Morganroth, Craig R Sprenger, Ofer Spiegelstein, Dorit Mimrod, Emil Samara, Laura Rabinovich
Publikováno v:
Clinical pharmacology in drug development. 8(1)
In this randomized double-blind study, 4 groups of healthy subjects (50 per arm) participated to evaluate the effect of laquinimod, an oral treatment in development for multiple sclerosis and Huntington disease, on the QTc interval. Subjects received
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f373baf3329a1792f08bf99280941be
https://pubmed.ncbi.nlm.nih.gov/29786964
https://pubmed.ncbi.nlm.nih.gov/29786964
Publikováno v:
Pharmaceutical Research. 30:3029-3044
Superior bioavailability of BCS Class 2 compounds incorporated into SNEDDS was previously reported. This study aims to elucidate the underlying mechanisms accountable for this phenomenon. SNEDDS of amiodarone (AM) and talinolol were developed. Pharma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::036eecf5bf7e09d4af872fb67fda1735
https://doi.org/10.1007/s11095-013-1063-y
https://doi.org/10.1007/s11095-013-1063-y
Autor:
Alena Y, Edwards, Anna, Elgart, Colm, Farrell, Ofra, Barnett-Griness, Laura, Rabinovich-Guilatt, Ofer, Spiegelstein
Publikováno v:
British journal of clinical pharmacology. 83(9)
Custirsen (OGX-011/TV-1011), a second-generation antisense oligonucleotide that reduces clusterin production, is under investigation with chemotherapy in prostate and lung cancer. This meta-analysis evaluated the population pharmacokinetics (PK) of c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::26320a3bee68321b4be9bc570574394e
https://pubmed.ncbi.nlm.nih.gov/28294391
https://pubmed.ncbi.nlm.nih.gov/28294391
Publikováno v:
Journal of Controlled Release. 160:401-406
Objective Preparation and characterization of an oral pro-dispersion liposphere formulation for cyclosporin, a water insoluble drug with limited bioavailability. Methods Pro-dispersion formulation consisted of a solid fat, dispersing agents and amphi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2c74453f0e5a980ca8060445c83f138
https://doi.org/10.1016/j.jconrel.2011.12.016
https://doi.org/10.1016/j.jconrel.2011.12.016